Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome

Unity Health Toronto

Status and phase: Completed; Phase 2

Conditions: Insulin Resistance Syndrome

Treatments: Dietary Supplement: konjac glucomannan; Dietary Supplement: wheat bran

Study type: Interventional

Funder types: Other

Identifiers

NCT03741686

Konjac in Insulin Resistance

Details and patient eligibility

About

To study whether a diet high in fiber from Konjac-mannan (KJM) has an effect on metabolic control in individuals with insulin resistance syndrome.

Enrollment: 11 patients

Sex: All

Ages: 45 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Impaired glucose tolerant
• Clinical absent of CHD
• BMI less than 30 kg/m2
• Presence of full insulin resistance syndrome
• Reduced HDL cholesterol
• Elevated serum triglycerides
• Moderate hypertension

Exclusion criteria

• Regular smoking
• Regular alcohol consumption
• Family history of premature coronary heart disease
• Hypothyroidism
• Renal, hepatic or gastrointestinal disease
• Taking medications for hyperglycemia
• Taking medications for hyperlipidemia
• Taking medications for hypertension

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

11 participants in 2 patient groups, including a placebo group

Konjac-mannan

Experimental group

Description:

Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.

Treatment:

Dietary Supplement: konjac glucomannan

Placebo

Placebo Comparator group

Description:

wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.

Treatment:

Dietary Supplement: wheat bran